<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607097</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-COD-2018-25</org_study_id>
    <nct_id>NCT03607097</nct_id>
  </id_info>
  <brief_title>Integral Management of Healthcare Problems Related With Drugs in Polimedicated Patients: Medication Code</brief_title>
  <official_title>Integral Management of Healthcare Problems Related With Drugs in Polimedicated Patients: Drug Code</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Although Drug- related Problems (DRPs) in polimedicated patients are a major public health
      problem in western countries and many of them have been considered avoidable, secondary and
      primary prevention policies have not been systematized, beyond pharmaceutical care programs
      in certain settings and on specific patients.

      Objectives:

      The main objective of this study is to evaluate the impact of implementing the Medication
      Code (CM) on patients who consult the emergency department for a DRP (secondary prevention of
      DRP). It is also intended to draw conclusions, based on the knowledge obtained in terms of
      DRP that will allow the establishment of future actions to reduce its prevalence (primary
      prevention actions).

      Method:

      A single-centre clinical trial is proposed in which adult patients will be selected to
      consult the Hospital Emergency Department (ED) of the Hospital de la Santa Creu i Sant Pau
      (HSCSP) for a primary or secondary diagnosis of DRP and will be randomised with a 1:1
      distribution to be included in the medication code (intervention group) or to receive usual
      care (control group). The intervention will be evaluated in terms of health outcomes (ED
      consultations and hospital readmission).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-centre clinical trial is proposed in which adult patients will be selected to
      consult the Hospital Emergency Department (ED) of the Hospital de la Santa Creu i Sant Pau
      (HSCSP) for a primary or secondary diagnosis of DRP and will be randomised with a 1:1
      distribution to be included in the medication code (intervention group) or to receive usual
      care (control group). The intervention will be evaluated in terms of health outcomes (ED
      consultations and hospital readmission).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 day readmission</measure>
    <time_frame>30 days</time_frame>
    <description>Readmissions during the 30 days after the intervention in any hospital centre from the &quot;Àrea Integral de Salut Barcelona Dreta&quot; after consulting the Hospital de la Santa Creu i Sant Pau (HSCSP) emergency department.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 day consultation</measure>
    <time_frame>30 days</time_frame>
    <description>Consultation 30 days after the intervention for any cause to the HSCSP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Any cause mortality 30 days after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on Emergency Department</measure>
    <time_frame>72 hours</time_frame>
    <description>Time from patient admission to discharge from the emergency department</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">808</enrollment>
  <condition>Drug Related Problems</condition>
  <condition>Pharmaceutical Care</condition>
  <arm_group>
    <arm_group_label>Secondary prevention of DRPs (medication code) (intervention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention consists of :1)Patient-centred prescription Espaulella-Panicot J model (review model that includes different strategies in a single intervention. It is performed by a multidisciplinary team, and allows them to adapt the pharmacological plan of patients with clinical complexity). 2)strategies to improve medication adherence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care (control group)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patient is reviewed according to the standard procedure, consisting only on the review of the medical prescription in the emergency department by the pharmacist assisting the unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Secondary prevention program for drug related problems</intervention_name>
    <description>The interventions consists of three stages: 1) actions aimed at improving the chronic prescription of the patient, 2) actions aimed at improving the therapeutic adherence and 3) actions aimed at improving the assistance healthcare levels coordination</description>
    <arm_group_label>Secondary prevention of DRPs (medication code) (intervention)</arm_group_label>
    <other_name>Medication Code</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  Drug Related Problems (DRP) related to drugs from Anatomical Therapeutic Chemical
             (ATC) groups A, B and C

        Exclusion Criteria:

          -  DRP due to autolytic attempt or final phase of life.

          -  Denied informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana M Juanes, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sante Creu i Sant Pau, Barcelona (Spain)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana M Juanes, PhD</last_name>
    <phone>+34932919000</phone>
    <phone_ext>1887</phone_ext>
    <email>ajuanes@santpau.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesus Ruiz, PhD</last_name>
    <phone>+34932919000</phone>
    <phone_ext>1887</phone_ext>
    <email>jrzrms@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Juanes</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Nivya K, Sri Sai Kiran V, Ragoo N, Jayaprakash B, Sonal Sekhar M. Systemic review on drug related hospital admissions - A pubmed based search. Saudi Pharm J. 2015 Jan;23(1):1-8. doi: 10.1016/j.jsps.2013.05.006. Epub 2013 May 30. Review.</citation>
    <PMID>25685036</PMID>
  </reference>
  <reference>
    <citation>Baena MI, Fajardo PC, Pintor-Mármol A, Faus MJ, Marín R, Zarzuelo A, Martínez-Olmos J, Martínez-Martínez F. Negative clinical outcomes of medication resulting in emergency department visits. Eur J Clin Pharmacol. 2014 Jan;70(1):79-87. doi: 10.1007/s00228-013-1562-0. Epub 2013 Oct 3.</citation>
    <PMID>24091839</PMID>
  </reference>
  <reference>
    <citation>Castro I, Guardiola JM, Tuneu L, Sala ML, Faus MJ, Mangues MA. Drug-related visits to the emergency department in a Spanish university hospital. Int J Clin Pharm. 2013 Oct;35(5):727-35. doi: 10.1007/s11096-013-9795-7. Epub 2013 May 22.</citation>
    <PMID>23695594</PMID>
  </reference>
  <reference>
    <citation>Patel P, Zed PJ. Drug-related visits to the emergency department: how big is the problem? Pharmacotherapy. 2002 Jul;22(7):915-23. Review.</citation>
    <PMID>12126224</PMID>
  </reference>
  <reference>
    <citation>Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, Leverve X, Lapostolle F, Borron SW, Adnet F; Association Pédagogique Nationale pour l'Enseignement de la Thérapeutique (APNET). Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007;30(1):81-8.</citation>
    <PMID>17194173</PMID>
  </reference>
  <reference>
    <citation>Wei L, Yang X, Li J, Liu L, Luo H, Zheng Z, Wei Y. Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study. J Thorac Dis. 2014 Jun;6(6):656-62. doi: 10.3978/j.issn.2072-1439.2014.06.20.</citation>
    <PMID>24976987</PMID>
  </reference>
  <reference>
    <citation>Obreli-Neto PR, Marusic S, Guidoni CM, Baldoni Ade O, Renovato RD, Pilger D, Cuman RK, Pereira LR. Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: a 36-month randomized controlled clinical trial. J Manag Care Spec Pharm. 2015 Jan;21(1):66-75.</citation>
    <PMID>25562774</PMID>
  </reference>
  <reference>
    <citation>Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008 Apr 14;168(7):687-94. doi: 10.1001/archinte.168.7.687. Review.</citation>
    <PMID>18413550</PMID>
  </reference>
  <reference>
    <citation>Ravn-Nielsen LV, Duckert ML, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS, Buck TC, Pottegård A, Hansen MR, Hallas J. Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission: A Randomized Clinical Trial. JAMA Intern Med. 2018 Mar 1;178(3):375-382. doi: 10.1001/jamainternmed.2017.8274.</citation>
    <PMID>29379953</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>secondary prevention</keyword>
  <keyword>pharmaceutical care</keyword>
  <keyword>drug related problems</keyword>
  <keyword>emergency department</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

